Dateline City:
KENILWORTH, N.J. & SEOUL, South Korea
First Product from Global Partnership to Deliver High-Quality Biosimilars to Help Meet Needs of Patients and Healthcare Systems Worldwide
KENILWORTH, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Samsung Bioepis Co., Ltd. today announced the approval of BRENZYS
(etanercept), a biosimilar of the immunology medicine Enbrel, by the
Ministry of Food and Drug Safety (MFDS) in Korea.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orSamsung BioepisMedia:Jamyung Cha, (82) 32-455-6137orInvestors:Sungjoon Park, (82) 32-455-6120
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more